Weston, FL – November 8, 2017 – BioMatrix SpRx, a growing leader in the specialty pharmacy industry, today announced the acquisition of Elwyn Pharmacy Group in Garnet Valley, Pennsylvania, 30 miles southwest of Philadelphia.
BioMatrix offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. The growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. BioMatrix excels in providing services for hemophilia and bleeding disorders, transplant therapy, IVIg and specialty care, and digital health technology.
Elwyn Pharmacy Group provides medications and supportive services for patients living with hard to treat disease states with the goal of achieving optimal patient outcomes. This is realized through compliance and individualized therapy management in an environment that maximizes patient satisfaction and adherence. Elwyn’s expertise in neurological and auto-immune disorders, fertility, oncology, and other chronic conditions has made them a leader in the specialty pharmacy industry.
As a result of this transaction, BioMatrix has expanded their services into complementary therapeutic categories requiring the same high-touch services they are accustomed to providing. BioMatrix’s national footprint increases to 11 pharmacy locations, nationwide, in key metropolitan locations. Elwyn joins the rapidly growing family of companies that comprise
BioMatrix including Matrix Health Group, Factor Support Network, Medex BioCare, and BiologicTx.
“The acquisition of Elwyn Pharmacy Group complements our strategy of bringing together leaders in the specialty pharmacy industry to provide comprehensive, compassionate care to patients living with complex, chronic diseases, “stated Bruce Greenberg, Chief Executive Officer, BioMatrix SpRx. “We are pleased to welcome Elwyn and their experienced staff to the BioMatrix family.”
“BioMatrix and Elwyn share very similar values. The success of both companies is rooted in our collaborative, compassionate patient-centered approach,” stated Nicholas Karalis, Chief Executive Officer, Elwyn Pharmacy Group. “Together, we expand our ability to provide a high level of individualized, focused care to patients living with a chronic condition. We are extremely excited to be part of this larger organization.”
About BioMatrix SpRx
BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes Matrix Health Group, Factor Support Network, Medex BioCare, BiologicTx.
About Elwyn Pharmacy Group
Elwyn Pharmacy Group provides a complete range of specialty pharmacy and infusion services. We treat a wide array of complex disease states such as Multiple Sclerosis, Hepatitis C and other GI related diseases, Oncology/Cancer, bleeding disorders, Rheumatoid Arthritis, Psoriasis and HIV. The Elwyn Pharmacy Group includes Elwyn Pharmacy, Glen Rock Medical Pharmacy, Elwyn Specialty Care, and Med Center Specialty Pharmacy.
Elwyn Pharmacy Group is excited to announce the addition of Marc Stranz PharmD as Vice President of Compliance. Marc has worked for more than 30 years in sterile pharmacy compounding and was an early leader in the home infusion industry. He has held branch, regional, and corporate positions with several national providers, including Senior Vice President for Clinical and Strategic Operations at Coram and Vice President of Clinical Operations and Regulatory Affairs at BioScrip. He was also Corporate Director of Infusion Services for Omnicare and Chief Clinical Officer for BioScrip Specialty Services.
A recognized business leader and subject matter expert, his work is part of the core practice standards of the industry established by professional organizations and regulatory bodies as well as the body of policy and procedure used by home infusion organizations. Dr Stranz pioneered safe and efficient provision of advanced infusion therapies in home infusion and has sustained involvement in cutting-edge therapies. His expertise includes clinical and operational services, regulatory compliance, accreditation, sterile compounding, and design/build of cleanrooms and infusion facilities. He served on the USP Expert Panel for Sterile Compounding, the Board of Pharmaceutical Specialties Practice Analysis Taskforce in Sterile Compounding, and the Institute of Environmental Sciences and Technology (IEST) Working Group for Controlled Environments per USP Chapter 797